We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Bicycle Therapeutics PLC Sponsored ADR (BCYC - Free Report) shares soared 9% in the last trading session to close at $22.83. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.
The sudden soaring of the stock price is likely due to the company's decision to move forward with the expedited development of BT8009 for metastatic bladder (urothelial) cancer after recent discussions with the FDA. Per Bicycle, the company has aligned with the FDA to conduct a registrational phase II/III Duravelo-2 study which could provide the basis for an accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer.
This company is expected to post quarterly loss of $1.06 per share in its upcoming report, which represents a year-over-year change of -10.4%. Revenues are expected to be $21.29 million, up 600.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Bicycle Therapeutics PLC Sponsored ADR, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BCYC going forward to see if this recent jump can turn into more strength down the road.
Bicycle Therapeutics PLC Sponsored ADR is part of the Zacks Medical - Biomedical and Genetics industry. Seattle Genetics , another stock in the same industry, closed the last trading session 1.8% higher at $208.13. SGEN has returned 5% in the past month.
For Seattle Genetics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.72. This represents a change of +30.1% from what the company reported a year ago. Seattle Genetics currently has a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 9.0%: Is This an Indication of Further Gains?
Bicycle Therapeutics PLC Sponsored ADR (BCYC - Free Report) shares soared 9% in the last trading session to close at $22.83. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.9% loss over the past four weeks.
The sudden soaring of the stock price is likely due to the company's decision to move forward with the expedited development of BT8009 for metastatic bladder (urothelial) cancer after recent discussions with the FDA. Per Bicycle, the company has aligned with the FDA to conduct a registrational phase II/III Duravelo-2 study which could provide the basis for an accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer.
This company is expected to post quarterly loss of $1.06 per share in its upcoming report, which represents a year-over-year change of -10.4%. Revenues are expected to be $21.29 million, up 600.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Bicycle Therapeutics PLC Sponsored ADR, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BCYC going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Bicycle Therapeutics PLC Sponsored ADR is part of the Zacks Medical - Biomedical and Genetics industry. Seattle Genetics , another stock in the same industry, closed the last trading session 1.8% higher at $208.13. SGEN has returned 5% in the past month.
For Seattle Genetics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.72. This represents a change of +30.1% from what the company reported a year ago. Seattle Genetics currently has a Zacks Rank of #4 (Sell).